Micronutrients in Management of Symptomatic Oral Lichen Planus

Status Completed

Clinical Trial Summary

Treatment of oral lichen planus is challenging. Diverse therapeutic modalities have been suggested, but a permanent cure is not yet available. In some OLP patients, topical corticosteroid alone is not sufficiently enough, thus it may require a supplementation to augment its effect. Micronutrients are gaining more attention as therapeutic modalities in immunologic disorders. Researchers are recommended to conduct further clinical studies are to assess the role of these elements in management of OLP (Gholizadeh & Sheykhbahaei, 2020). Among the less visited micronutrients are zinc and vitamin D. This trial will assess their role in management of OLP.

Clinical Trial Description

The enrolled patients will be divided randomly into three groups. One group will receive topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm) four times daily, the second group will receive topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm) four times daily with systemic zinc (Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma) twice daily and the third group will receive topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm) four times daily with systemic vitamin D (Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals) once daily. The patients will be recalled weekly for eight weeks. For every four weeks of topical corticosteroid application, topical oral antifungal (Daktarin 2% oral gel - miconazole) will be prescribed, four times daily for one week, to all the patients in the trial, to avoid secondary infection with oral candidiasis. The patients will be asked to prohibit the use of any topical or systemic medication during the trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04765267
Study type	Interventional
Source	Cairo University
Contact
Status	Completed
Phase	N/A
Start date	April 1, 2021
Completion date	September 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05997173` - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed	`NCT02443311` - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus	Phase 4
Completed	`NCT00484250` - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other	Phase 2
Completed	`NCT03682562` - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Not yet recruiting	`NCT06428630` - Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus	Early Phase 1
Completed	`NCT04193748` - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)	Phase 4
Completed	`NCT04153266` - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting	`NCT06135805` - Impact of Fluocinonide 0,05% in Oral Lichen Planus	N/A
Completed	`NCT04289233` - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed	`NCT04293718` - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed	`NCT00525421` - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus	Phase 2
Not yet recruiting	`NCT04091698` - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial	Phase 1
Completed	`NCT03386643` - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus	Phase 2
Withdrawn	`NCT03836885` - Apremilast - Oral Lichen Planus Trial	Phase 2
Completed	`NCT05730855` - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed	`NCT03257228` - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)	N/A
Recruiting	`NCT03026478` - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus	Phase 2
Completed	`NCT02834520` - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus	N/A
Completed	`NCT02858297` - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus	Phase 4
Completed	`NCT02106468` - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus	Phase 2